Aktis Oncology
Develops targeted radiopharmaceuticals for solid tumors using miniprotein radioconjugates.
$25.78
After-hours close+0.02 (+0.06%)
At close$25.77(−1.59%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 64.32%Insiders —
Shares outstanding 53.40M · Float 483.1K · 0.9% free float
Insiders — no current Form 4 position.
Institutions13F, as of Jun 30, 2026
116 holders · 34.35M shares · 55 new positions · 83 increased · 17 reduced · 8 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Bioimpact Capital LLC | 4.84M | 9.06% | 0 | Aug 14, 2026 |
| Ecor1 Capital, LLC | 4.82M | 9.03% | 0 | Aug 14, 2026 |
| Blue Owl Capital Holdings LP | 3.07M | 5.75% | −91.1K | Aug 11, 2026 |
| BlackRock, Inc. | 2.28M | 4.27% | +166.2K | Aug 7, 2026 |
| T. Rowe Price Investment Management, Inc. | 2.05M | 3.84% | −72.4K | Aug 14, 2026 |
| Wellington Management Group LLP | 1.97M | 3.68% | −350.8K | Aug 14, 2026 |
| RTW Investments, LP | 1.59M | 2.98% | 0 | Aug 14, 2026 |
| Ra Capital Management, L.P. | 1.31M | 2.46% | −188.7K | Aug 14, 2026 |
Beneficial owners13D/G · 5% or more, as filed
No 13D/G filer at 5% or more on record.
InsidersForm 4
| Insider | Role | Shares | Filed |
|---|---|---|---|
| ELI LILLY & Co | 10 percent owner | 6.34M | Jan 15, 2026 |
1 ten-percent owner holds 6.34M shares by Form 4, outside the officers-and-directors figure above
Latest trades
Nothing filed in the last 12 months.
CongressHouse and Senate disclosures
Not reported.